Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANN C MOORE

Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner

NPI
1184840712
CMS profile
11085205
Location
GLENDALE, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$15,430.54

59 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANN C MOORE

NPI 1184840712 · CMS profile ID 11085205

Physician Assistants & Advanced Practice Nursing Providers / Nurse Practitioner

GLENDALE, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1184840712?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANN C MOORE, NPI 1184840712, CMS profile ID 11085205. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1184840712?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ANN C MOORE, NPI 1184840712, CMS profile ID 11085205. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1184840712?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ANN C MOORE, NPI 1184840712, CMS profile ID 11085205, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1184840712?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

59 matching records · $15,430.54 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 59 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–59 of 59.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $240.0003/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845855993 CMS
Merck Sharp & Dohme Corporation $19.7703/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848544221 CMS
JAZZ PHARMACEUTICALS INC. $16.4003/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845581519 CMS
AbbVie Inc. $23.7702/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794975115 CMS
Intercept Pharmaceuticals, Inc. $780.0002/08/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836226663 CMS
Intercept Pharmaceuticals, Inc. $195.0002/08/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836226665 CMS
AbbVie Inc. $675.0002/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794975111 CMS
Intercept Pharmaceuticals, Inc. $16.1801/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836226659 CMS
Intercept Pharmaceuticals, Inc. $375.0001/20/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836226657 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $15,430.54 59
PY2022 $32,151.60 108
PY2023 $39,658.95 110
PY2024 $71,467.29 179
PY2025 $49,062.44 159

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,023,373.48 134
PY2024 Principal investigator $475,093.40 49
PY2022 Principal investigator $112,310.59 27
PY2021 Principal investigator $278,431.62 355

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

134 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Madrigal Pharmaceuticals $1,295.00 12/22/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248254760
Principal investigator 1 Madrigal Pharmaceuticals $1,534.40 12/22/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248254764
Principal investigator 1 Madrigal Pharmaceuticals $11,414.26 12/19/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254485
Principal investigator 1 Madrigal Pharmaceuticals $31,185.00 12/19/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254493
Principal investigator 1 Madrigal Pharmaceuticals $945.00 12/19/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254497
Principal investigator 1 Madrigal Pharmaceuticals $150.00 12/19/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254501
Principal investigator 1 Madrigal Pharmaceuticals $3,834.68 12/19/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254505
Principal investigator 1 Madrigal Pharmaceuticals $135.00 12/11/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253982
Principal investigator 1 Madrigal Pharmaceuticals $13,567.50 12/11/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253985
Principal investigator 1 Madrigal Pharmaceuticals $150.00 12/04/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253428
Principal investigator 1 Madrigal Pharmaceuticals $1,957.50 12/04/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253433
Principal investigator 1 Madrigal Pharmaceuticals $100.00 12/04/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253441
Principal investigator 1 Madrigal Pharmaceuticals $12,055.52 12/04/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253490
Principal investigator 1 Madrigal Pharmaceuticals $4,764.49 11/25/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252976
Principal investigator 1 Madrigal Pharmaceuticals $19,905.73 11/18/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248252695
Principal investigator 1 Madrigal Pharmaceuticals $2,475.23 11/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252625
Principal investigator 1 Madrigal Pharmaceuticals $2,475.23 10/29/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252198
Principal investigator 1 Madrigal Pharmaceuticals $7,416.50 10/27/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248252111
Principal investigator 1 Madrigal Pharmaceuticals $2,154.60 10/23/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251968
Principal investigator 1 Madrigal Pharmaceuticals $4,629.83 10/16/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251557
Principal investigator 1 Madrigal Pharmaceuticals $2,154.60 10/09/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251446
Principal investigator 1 Madrigal Pharmaceuticals $19,265.92 10/09/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251451
Principal investigator 1 Madrigal Pharmaceuticals $4,629.83 10/03/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251190
Principal investigator 1 Madrigal Pharmaceuticals $188.50 10/02/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248250823
Principal investigator 1 Madrigal Pharmaceuticals $292.50 10/02/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248250827
Principal investigator 1 Madrigal Pharmaceuticals $9,307.50 10/02/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248250838
Principal investigator 1 Madrigal Pharmaceuticals $4,629.83 09/23/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250628
Principal investigator 1 Madrigal Pharmaceuticals $7,425.69 09/23/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250632
Principal investigator 1 Madrigal Pharmaceuticals $1,485.40 09/23/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248250641
Principal investigator 1 Madrigal Pharmaceuticals $1,485.40 09/23/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248250645
Principal investigator 1 Madrigal Pharmaceuticals $9,259.66 09/18/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250373
Principal investigator 1 Madrigal Pharmaceuticals $44,752.50 09/18/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250381
Principal investigator 1 Madrigal Pharmaceuticals $945.00 09/18/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250385
Principal investigator 1 Madrigal Pharmaceuticals $810.00 09/18/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250389
Principal investigator 1 Madrigal Pharmaceuticals $40,770.00 09/18/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250394
Principal investigator 1 Madrigal Pharmaceuticals $292.50 09/12/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248249977
Principal investigator 1 Madrigal Pharmaceuticals $4,374.50 09/12/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248249981
Principal investigator 1 Madrigal Pharmaceuticals $4,309.20 09/12/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248249987
Principal investigator 1 Madrigal Pharmaceuticals $31,860.00 09/12/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248249991
Principal investigator 1 Madrigal Pharmaceuticals $675.00 09/12/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248249994
Principal investigator 1 Madrigal Pharmaceuticals $336.00 09/05/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248249790
Principal investigator 1 Madrigal Pharmaceuticals $6,463.80 09/04/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248249663
Principal investigator 1 Madrigal Pharmaceuticals $13,944.00 09/02/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248249356
Principal investigator 1 Madrigal Pharmaceuticals $49.00 09/02/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248249360
Principal investigator 1 Madrigal Pharmaceuticals $12,705.00 09/02/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248249364
Principal investigator 1 Madrigal Pharmaceuticals $12,705.00 09/02/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248249369
Principal investigator 1 Madrigal Pharmaceuticals $390.00 09/01/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248249316
Principal investigator 1 Madrigal Pharmaceuticals $12,304.50 09/01/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248249319
Principal investigator 1 Madrigal Pharmaceuticals $2,154.60 08/26/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248249189
Principal investigator 1 Madrigal Pharmaceuticals $3,080.75 08/26/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248249196
Principal investigator 1 Madrigal Pharmaceuticals $17,409.96 08/21/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248955
Principal investigator 1 Madrigal Pharmaceuticals $6,054.75 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248540
Principal investigator 1 Madrigal Pharmaceuticals $50.00 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248544
Principal investigator 1 Madrigal Pharmaceuticals $2,068.25 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248548
Principal investigator 1 Madrigal Pharmaceuticals $100.00 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248553
Principal investigator 1 Madrigal Pharmaceuticals $4,036.50 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248557
Principal investigator 1 Madrigal Pharmaceuticals $9,045.00 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248561
Principal investigator 1 Madrigal Pharmaceuticals $540.00 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248564
Principal investigator 1 Madrigal Pharmaceuticals $3,915.00 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248568
Principal investigator 1 Madrigal Pharmaceuticals $1,917.34 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248572
Principal investigator 1 Madrigal Pharmaceuticals $100.00 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248576
Principal investigator 1 Madrigal Pharmaceuticals $2,025.00 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248579
Principal investigator 1 Madrigal Pharmaceuticals $135.00 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248584
Principal investigator 1 Madrigal Pharmaceuticals $2,018.25 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248588
Principal investigator 1 Madrigal Pharmaceuticals $14,580.00 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248592
Principal investigator 1 Madrigal Pharmaceuticals $100.00 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248596
Principal investigator 1 Madrigal Pharmaceuticals $4,455.00 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248599
Principal investigator 1 Madrigal Pharmaceuticals $405.00 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248604
Principal investigator 1 Madrigal Pharmaceuticals $9,045.00 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248608
Principal investigator 1 Madrigal Pharmaceuticals $150.00 08/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248612
Principal investigator 1 Madrigal Pharmaceuticals $14,408.91 08/07/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248199
Principal investigator 1 Madrigal Pharmaceuticals $20,839.39 07/31/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248247909
Principal investigator 1 Madrigal Pharmaceuticals $450.00 07/31/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247919
Principal investigator 1 Madrigal Pharmaceuticals $2,970.00 07/31/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247922
Principal investigator 1 Madrigal Pharmaceuticals $2,018.25 07/31/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247927
Principal investigator 1 Madrigal Pharmaceuticals $370.50 07/23/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248247505
Principal investigator 1 Madrigal Pharmaceuticals $975.00 07/23/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248247509
Principal investigator 1 Madrigal Pharmaceuticals $2,154.60 07/22/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247473
Principal investigator 1 Madrigal Pharmaceuticals $2,154.60 07/17/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247196
Principal investigator 1 Madrigal Pharmaceuticals $33,909.40 07/11/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248247050
Principal investigator 1 Madrigal Pharmaceuticals $2,475.23 07/10/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246957
Principal investigator 1 Madrigal Pharmaceuticals $3,111.32 07/10/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248246961
Principal investigator 1 Madrigal Pharmaceuticals $4,309.20 07/04/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246567
Principal investigator 1 Madrigal Pharmaceuticals $486.00 07/01/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248246265
Principal investigator 1 Madrigal Pharmaceuticals $3,186.00 07/01/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248246269
Principal investigator 1 Madrigal Pharmaceuticals $15,723.46 06/24/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246081
Principal investigator 1 Madrigal Pharmaceuticals $9,779.08 06/12/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245371
Principal investigator 1 Madrigal Pharmaceuticals $5,062.50 06/12/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245385
Principal investigator 1 Madrigal Pharmaceuticals $500.00 06/12/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245389
Principal investigator 1 Madrigal Pharmaceuticals $50.00 06/12/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245393
Principal investigator 1 Madrigal Pharmaceuticals $487.50 06/02/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248244793
Principal investigator 1 Madrigal Pharmaceuticals $78.00 06/02/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248244797
Principal investigator 1 Madrigal Pharmaceuticals $4,950.46 05/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244611
Principal investigator 1 Madrigal Pharmaceuticals $675.00 05/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244620
Principal investigator 1 Madrigal Pharmaceuticals $41,580.00 05/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244623
Principal investigator 1 Madrigal Pharmaceuticals $150.00 05/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244628
Principal investigator 1 Madrigal Pharmaceuticals $600.00 05/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244631
Principal investigator 1 Madrigal Pharmaceuticals $6,075.00 05/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244636
Principal investigator 1 Madrigal Pharmaceuticals $17,829.70 05/23/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248244433
Principal investigator 1 Madrigal Pharmaceuticals $11,747.71 05/22/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244268
Principal investigator 1 Madrigal Pharmaceuticals $97.50 05/15/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243756
Principal investigator 1 Madrigal Pharmaceuticals $1,307.80 05/15/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243760
Principal investigator 1 Madrigal Pharmaceuticals $18,333.35 05/15/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243773
Principal investigator 1 Madrigal Pharmaceuticals $78.00 05/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243403
Principal investigator 1 Madrigal Pharmaceuticals $390.00 05/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243407
Principal investigator 1 Madrigal Pharmaceuticals $11,115.00 05/14/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243411
Principal investigator 1 Madrigal Pharmaceuticals $780.00 05/07/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243238
Principal investigator 1 Madrigal Pharmaceuticals $4,829.50 05/07/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243242
Principal investigator 1 Madrigal Pharmaceuticals $3,780.00 05/02/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243027
Principal investigator 1 Madrigal Pharmaceuticals $21,195.00 05/02/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243031
Principal investigator 1 Madrigal Pharmaceuticals $540.00 05/02/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243035
Principal investigator 1 Madrigal Pharmaceuticals $7,474.40 04/28/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248242785
Principal investigator 1 Madrigal Pharmaceuticals $9,152.50 04/10/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242048
Principal investigator 1 Madrigal Pharmaceuticals $900.00 04/10/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242052
Principal investigator 1 Madrigal Pharmaceuticals $1,500.00 04/10/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242056
Principal investigator 1 Madrigal Pharmaceuticals $26,214.33 04/08/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248241815
Principal investigator 1 Madrigal Pharmaceuticals $21,330.00 03/06/2025 Non-covered Recipient Entity
ARIZONA LIVER HEALTH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240212
Principal investigator 1 Madrigal Pharmaceuticals $6,562.50 03/06/2025 Non-covered Recipient Entity
ARIZONA LIVER HEALTH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240216
Principal investigator 1 Madrigal Pharmaceuticals $15,284.75 03/06/2025 Non-covered Recipient Entity
ARIZONA LIVER HEALTH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240220
Principal investigator 1 Madrigal Pharmaceuticals $13,500.00 03/06/2025 Non-covered Recipient Entity
ARIZONA LIVER HEALTH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240227
Principal investigator 1 Madrigal Pharmaceuticals $49,863.56 03/06/2025 Non-covered Recipient Entity
ARIZONA LIVER HEALTH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240231
Principal investigator 1 Madrigal Pharmaceuticals $2,609.89 03/06/2025 Non-covered Recipient Entity
ARIZONA LIVER HEALTH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240236
Principal investigator 1 Madrigal Pharmaceuticals $6,633.25 02/06/2025 Non-covered Recipient Entity
ARIZONA LIVER HEALTH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239067
Principal investigator 1 Madrigal Pharmaceuticals $45,028.58 02/06/2025 Non-covered Recipient Entity
ARIZONA LIVER HEALTH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239073
Principal investigator 1 Madrigal Pharmaceuticals $13,674.00 01/30/2025 Non-covered Recipient Entity
ARIZONA LIVER HEALTH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238859
Principal investigator 1 Madrigal Pharmaceuticals $2,068.25 01/23/2025 Non-covered Recipient Entity
ARIZONA LIVER HEALTH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238656
Principal investigator 1 Madrigal Pharmaceuticals $23,220.00 01/23/2025 Non-covered Recipient Entity
ARIZONA LIVER HEALTH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238694
Principal investigator 1 Madrigal Pharmaceuticals $11,070.00 01/23/2025 Non-covered Recipient Entity
ARIZONA LIVER HEALTH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238724
Principal investigator 1 Madrigal Pharmaceuticals $1,761.75 01/09/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248238159
Principal investigator 1 Madrigal Pharmaceuticals $101.25 01/09/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248238163
Principal investigator 1 Madrigal Pharmaceuticals $1,331.10 01/09/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248238167
Principal investigator 1 Madrigal Pharmaceuticals $4,300.00 01/09/2025 Non-covered Recipient Entity
ARIZONA LIVER HEALTH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238277
Principal investigator 1 Madrigal Pharmaceuticals $33,075.00 01/09/2025 Non-covered Recipient Entity
ARIZONA LIVER HEALTH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238299
Principal investigator 1 Madrigal Pharmaceuticals $1,823.71 01/06/2025 Non-covered Recipient Entity
THE INSTITUTE FOR LIVER HEALTH II LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248238060